Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Nasopharyngeal Carcinoma 20Carcinoma, Non-Small-Cell Lung 18Esophageal Squamous Cell Carcinoma 15Breast Neoplasms 14Triple Negative Breast Neoplasms 13Squamous Cell Carcinoma of Head and Neck 11Carcinoma, Hepatocellular 11Stomach Neoplasms 8Small Cell Lung Carcinoma 8Uterine Cervical Neoplasms 6Recurrence 6Head and Neck Neoplasms 6Colorectal Neoplasms 6Carcinoma, Transitional Cell 5Carcinoma, Renal Cell 5Urinary Bladder Neoplasms 4Sarcoma 4Rectal Neoplasms 4Neoplasm Metastasis 4Melanoma 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Locally Advanced Rectal Cancer 3Liver Neoplasms 3Turcot syndrome 2Pathologic Complete Response 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Nasopharyngeal Neoplasms 2

Interventions

toripalimab 2zanidatamab 1tislelizumab 1disitamab vedotin 1Probiotics 1Gemcitabine 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Muscle Invasive Bladder Cancer (MIBC) × toripalimab × Clear all
NCT07474064 2026-03-17

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
146 enrolled
Genitourinary

Muscle Invasive Bladder Cancer (MIBC)

NCT07201675 2025-10-01

Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment

Qilu Hospital of Shandong University

Phase 2 Not yet recruiting
59 enrolled
Genitourinary

Muscle Invasive Bladder Cancer (MIBC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡